
Phase III trial initiated for enzalutamide in treatment of prostate cancer
pharmafile | March 24, 2016 | News story | Research and Development | Astellas, Medivation, arches, clinical trial, enzalutamide, phase 3, phase III, prostate cancer
Astellas Pharma (TSE: 4503) and Medivation (NASDAQ:MDVN) have announced the initiation of the ARCHES Phase III clinical trial to evaluate the safety and efficacy of enzalutamide in patients with metastatic hormone sensitive prostate cancer.
Enzalutamide will be combined with androgen deprivation therapy (ADT) and evaluated versus placebo in the trial. ADT is the standard of care for patients with this form of prostate cancer and the trial will examine how the addition of enzalutamide will benefit patients, compared to ADT alone.
Claire Thom, oncology therapeutic head at Astellas, says: “Dosing of the first patient in this trial demonstrates our ongoing commitment to continuing to investigate enzalutamide.”
Mohammed Hirmand, interim chief medical officer at Medivation, comments: “This trial targets an important patient population as we advance the development of enzalutamide. The initiation of this trial demonstrates our ongoing commitment to fully develop enzalutamide in this serious disease.”
Sean Murray
Related Content

Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

How will biomarker-led diagnostics reshape respiratory medicine?
By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …

Blue Earth announces first UK patient received prostate cancer injection
Blue Earth Therapeutics, a clinical-stage company specialising in targeted radiotherapeutics, has announced that the first …






